Evaluation of residual promoter activity in γ-retroviral self-inactivating (SIN) vectors

Molecular Therapy

Volumn 20, Issue 1, 2012, Pages 84-90

  Xu, Wenqin ^a   Russ, Jill L ^a   Eiden, Maribeth V ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; MESSENGER RNA; RETROVIRUS VECTOR;

ARTICLE; CONTROLLED STUDY; ENHANCER REGION; GENE ACTIVATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE VECTOR; LONG TERMINAL REPEAT; MURINE LEUKEMIA VIRUS; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; SELF INACTIVATING VECTOR; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM;

MURINE LEUKEMIA VIRUS;

EID: 84856970149     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.204     Document Type: Article

References (33)

1. Hacein-Bey-Abina, S, de Saint Basile, G and Cavazzana-Calvo, M (2003). Gene therapy of X-linked severe combined immunodeficiency. Methods Mol Biol 215: 247-259.
2. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
3. Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256. (Pubitemid 36077924)
4. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419. (Pubitemid 37296260)
5. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
6. Hanawa, H, Persons, DA and Nienhuis, AW (2005). Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors. J Virol 79: 8410-8421. (Pubitemid 40853543)
7. Finer, MH, Dull, TJ, Qin, L, Farson, D and Roberts, MR (1994). kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 83: 43-50. (Pubitemid 24016514)
8. Bosticardo, M, Ghosh, A, Du, Y, Jenkins, NA, Copeland, NG and Candotti, F (2009). Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells. Mol Ther 17: 1910-1918.
9. Bruce, JW, Ahlquist, P and Young, JA (2008). The host cell sulfonation pathway contributes to retroviral infection at a step coincident with provirus establishment. PLoS Pathog 4: e1000207.
10. Cassani, B, Montini, E, Maruggi, G, Ambrosi, A, Mirolo, M, Selleri, S et al. (2009). Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. Blood 114: 3546-3556.
11. De Palma, M, Montini, E, Santoni de Sio, FR, Benedicenti, F, Gentile, A, Medico, E et al. (2005). Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105: 2307-2315. (Pubitemid 40387024)
12. Hahm, SH, Yi, Y, Lee, DK, Noh, MJ, Yun, L, Hwang, S et al. (2004). Construction of retroviral vectors with enhanced efficiency of transgene expression. J Virol Methods 121: 127-136. (Pubitemid 39295702)
13. Jaalouk, DE, Crosato, M, Brodt, P and Galipeau, J (2006). Inhibition of histone deacetylation in 293GPG packaging cell line improves the production of selfinactivating MLV-derived retroviral vectors. Virol J 3: 27.
14. Julius, MA, Yan, Q, Zheng, Z and Kitajewski, J (2000). Q vectors, bicistronic retroviral vectors for gene transfer. BioTechniques 28: 702-708. (Pubitemid 30198606)
15. Modlich, U, Bohne, J, Schmidt, M, von Kalle, C, Knöss, S, Schambach, A et al. (2006). Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108: 2545-2553.
16. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Bartholomae, CC, Ranzani, M et al. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119: 964-975.
17. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Ponzoni, M, Bartholomae, C et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696. (Pubitemid 43882120)
18. Zaiss, AK, Son, S and Chang, LJ (2002). RNA 3' readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol 76: 7209-7219.
19. Kraunus, J, Schaumann, DH, Meyer, J, Modlich, U, Fehse, B, Brandenburg, G et al. (2004). Self-inactivating retroviral vectors with improved RNA processing. Gene Ther 11: 1568-1578. (Pubitemid 39433477)
20. Marty, L, Roux, P, Royer, M and Piechaczyk, M (1990). MoMuLV-derived selfinactivating retroviral vectors possessing multiple cloning sites and expressing the resistance to either G418 or hygromycin B. Biochimie 72: 885-887.
21. Titeux, M, Pendaries, V, Zanta-Boussif, MA, Décha, A, Pironon, N, Tonasso, L et al. (2010). SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa. Mol Ther 18: 1509-1518.
22. Yu, SF, von Rüden, T, Kantoff, PW, Garber, C, Seiberg, M, Rüther, U et al. (1986). Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 83: 3194-3198.
23. Zufferey, R, Dull, T, Mandel, RJ, Bukovsky, A, Quiroz, D, Naldini, L et al. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72: 9873-9880. (Pubitemid 28520853)
24. Linney, E, Davis, B, Overhauser, J, Chao, E and Fan, H (1984). Non-function of a Moloney murine leukaemia virus regulatory sequence in F9 embryonal carcinoma cells. Nature 308: 470-472. (Pubitemid 14130924)
25. Golemis, EA, Speck, NA and Hopkins, N (1990). Alignment of U3 region sequences of mammalian type C viruses: identification of highly conserved motifs and implications for enhancer design. J Virol 64: 534-542. (Pubitemid 20032663)
26. Olson, P, Nelson, S and Dornburg, R (1994). Improved self-inactivating retroviral vectors derived from spleen necrosis virus. J Virol 68: 7060-7066. (Pubitemid 24328756)
27. Olson, P, Temin, HM and Dornburg, R (1992). Unusually high frequency of reconstitution of long terminal repeats in U3-minus retrovirus vectors by DNA recombination or gene conversion. J Virol 66: 1336-1343.
28. Ory, DS, Neugeboren, BA and Mulligan, RC (1996). A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 93: 11400-11406. (Pubitemid 26347133)
29. Dornburg, R and Temin, HM (1988). Retroviral vector system for the study of cDNA gene formation. Mol Cell Biol 8: 2328-2334.
30. Cornils, K, Lange, C, Schambach, A, Brugman, MH, Nowak, R, Lioznov, M et al. (2009). Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance. Mol Ther 17: 131-143.
31. Thornhill, SI, Schambach, A, Howe, SJ, Ulaganathan, M, Grassman, E, Williams, D et al. (2008). Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther 16: 590-598. (Pubitemid 351315000)
32. Herzog, RW (2010). Gene therapy for SCID-X1: round 2. Mol Ther 18: 1891.
33. Lander, MR and Chattopadhyay, SK (1984). A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses. J Virol 52: 695-698. (Pubitemid 15200225)